Cashing in with off-the-shelf CAR Ts
Nature Reviews Drug Discovery 17, 307 (2018).
doi:10.1038/nrd.2018.69
Author: Asher Mullard
Allogene Therapeutics is taking over rights to Pfizer's off-the-shelf chimeric antigen receptor (CAR) T cell pipeline, backed by US$300 million from one of the largest series A funding rounds in the history of biotech.Last year the FDA approved the first ever CAR Ts,
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research